(Q35101473)

6 August 2017

1 reference

title

Thalidomide for erythema nodosum leprosum and other applications (English)

1 reference

Erythema nodosum leprosum

6 August 2017

0 references

1 reference

1 reference

Mark C Okafor

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

23

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

481-493

1 reference

Potential novel uses of thalidomide: focus on palliative care

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide: current and potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Topical and systemic therapy for recurrent aphthous stomatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide for previously untreated indolent or smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

The rationale and future potential of angiogenesis inhibitors in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide hypersensitivity in AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thrombotic accidents induced by thalidomide: two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thromboembolism in patients on thalidomide for myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide-associated deep vein thrombosis and pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Thalidomide treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Epidemiology and clinical features of HIV-1 associated neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

HIV-associated neuropathies: role of HIV-1, CMV, and other viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

Didanosine: an updated review of its use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.4.481.32115

10.1592/PHCO.23.4.481.32115

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference